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Abstract 
Background: The advantages of photodynamic diagnostic technology using 5-aminolevulinic acid (ALA-PDD) have 
been established. The aim of this prospective cohort study was to evaluate the usefulness of ALA-PDD to diagnose 
upper tract urothelial carcinoma (UT-UC) using the Olympus VISERA ELITE video system.
Methods: We carried out a prospective, interventional, non-randomized, non-contrast and open label cohort pilot 
study that involved patients who underwent ureterorenoscopy (URS) to detect UT-UC. 5-aminolevulinic acid hydro-
chloride was orally administered before URS. The observational results and pathological diagnosis with ALA-PDD 
and traditional white light methods were compared, and the proportion of positive subjects and specimens were 
calculated.
Results: A total of 20 patients were enrolled and one patient who had multiple bladder tumors did not undergo 
URS. Fifteen of 19 patients were pathologically diagnosed with UT-UC and of these 11 (73.3%) were ALA-PDD posi-
tive. Fourteen of 19 patients were ALA-PDD positive and of these 11 were pathologically diagnosed with UC. For the 
92 biopsy specimens that were malignant or benign, the sensitivity for both traditional white light observation and 
ALA-PDD was the same at 62.5%, whereas the specificities were 73.1% and 67.3%, respectively. Of the 38 specimens 
that were randomly biopsied without any abnormality under examination by both white light and ALA-PDD, 11 speci-
mens (28.9%) from 5 patients were diagnosed with high grade UC. In contrast, four specimens from 4 patients, which 
were negative in traditional white light observation but positive in ALA-PDD, were diagnosed with carcinoma in situ 
(CIS).
Conclusions: Our results suggest that ALA-PDD using VISERA ELITE is not sufficiently applicable for UT-UC. Neverthe-
less, it might be better particularly for CIS than white light and superior results would be obtained using VISERA ELITE 
II video system.
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Background
Photodynamic diagnostic (PDD) technology using 
5-aminolevulinic acid (ALA-PDD) is currently being 
used for the diagnosis of brain tumors in Japan. For 
patients with bladder cancer, the sensitivity and speci-
ficity of ALA-PDD using scopes and video systems 
produced by Karl Storz SE & Co. KG (Tuttlingen, Ger-
many) can be as high as 75.8% and 68.2%, respectively 
[1]. Thus, in 2017 Japanese national health insurance 
approved ALA-PDD for visualization of non-muscle-
invasive bladder cancer at the time of transurethral 
resection of bladder tumors (TURBT). ALA is an 
amino acid that is naturally present in living animals 
and plants, as well as in commonly consumed foods 
and beverages, and protoporphyrin IX (PpIX), which 
is also present in the human body. Neither compound 
shows toxicity and the safety of both has been con-
firmed in healthy individuals [2]. The premise for ALA-
PDD is that orally ingested ALA accumulates as PpIX 
in tumor cells to a greater degree than in normal cells. 
Upon excitation with visible blue light (375–445  nm), 
PpIX emits red light (600–740 nm).
Upper tract urothelial carcinoma (UT-UC) includes 
renal pelvic and ureteral cancer, which are the same 
as bladder cancer from a pathological perspective. 
Although standard treatment for UT-UC is total neph-
roureterectomy and partial cystectomy, techniques 
involving endoscopic diagnosis and resection with URS 
have been developed [3, 4]. However, small satellite 
tumors, flat tumors and carcinoma in situ (CIS) in the 
upper urinary tract are difficult to diagnose and treat 
endoscopically [5, 6]. ALA-PDD allows visualization 
of lesions that cannot be diagnosed by conventional 
observation using white light, thus increasing the like-
lihood of accurate diagnosis and effective treatment 
in patients with UT-UC [7, 8]. ALA-PDD performed 
for UT-UC patients using a ureteroscope and a video 
system produced by Karl Storz SE & Co. KG. has been 
described [9, 10], but no similar study has been carried 
out using a video system manufactured by Olympus 
Co., Ltd. (Tokyo, Japan).
The aim of this prospective cohort study was to evalu-
ate the usefulness of ALA-PDD for diagnosis of UT-UC 
using the VISERA ELITE video system produced by 
Olympus Co., Ltd.
Methods
All methods were carried out in accordance with relevant 
guidelines and regulations.
Study design
We carried out a pilot, prospective interventional, non-
randomized, non-contrast and open label cohort study. 
Enrollment began following approval by the review 
board. Patients who were suspected of having UT-UC 
and were undergoing ureterorenoscopy (URS) were 
enrolled. Since this study was a pilot study, 20 cases were 
considered based on the annual number of cases treated 
at our institution. The primary endpoint was the propor-
tion of positive subjects and secondary endpoints were 
sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and adverse events for 
ALA-PDD.
Patients
Patients that were enrolled in the study were adults who 
were suspected of having UT-UC and were undergoing 
URS. All patients were aware of the conditions associated 
with the disease, and provided informed consent to par-
ticipate. All enrolled patients agreed to use contraception 
until 1 month after the administration of 5-ALA. Exclu-
sion criteria were patients with porphyria, allergy to por-
phyrin or 5-ALA, hepatic dysfunction, use of drugs that 
induced photosensitivity, pregnancy, or severe underly-
ing diseases such as cardiovascular diseases or infection.
Protocols
On the day of the URS, 20  mg/kg of 5-aminolevulinic 
acid hydrochloride (5-ALA HCl) was orally adminis-
tered over 180  min (range: 120–240  min) before the 
scheduled insertion time for the ureteroscope. After oral 
administration of 5-ALA HCl, patients drank 250 mL of 
an L-arginine-intensive drink and 500  mL of fruit juice 
to maintain blood pressure. At the time of examination, 
normal observations using white light and ALA-PDD 
using visible blue light were carried out using a two-
color LED light source (ALADUCK LS-DLED, SBI Phar-
maceuticals, Tokyo, Japan). All endoscopic images were 
recorded.
After the procedures, patients had proper shading to 
prevent photosensitivity for up to 48  h after ingesting 
Trial registration: The present clinical study was approved by the Okayama University Institutional Review Board prior 
to study initiation (Application no.: RIN 1803–002) and was registered with the UMIN Clinical Trials Registry (UMIN-
CTR), Japan (Accession no.: UMIN000031205).
Keywords: Photodynamic diagnosis, 5-Aminolevulinic acid, ALA-PDD, Upper urinary tract urothelial carcinoma, 
VISERA ELITE video system
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5-ALA HCl and light exposure of less than 500  lx was 
maintained. Hematologic and biochemical examinations 
were performed on postoperative days (POD) 1 and 3 
and the occurrence of adverse events was noted.
5‑ALA (5‑aminolevulinic acid)
5-ALA HCl was supplied as a white powder similar to 
that for ALAGLIO by SBI Pharmaceuticals (SBI Phar-
maceuticals, Tokyo, Japan). The chemical compound was 
stored according to strict quality control guidelines and 
detailed usage records were maintained by the Division 
of Clinical Research of New Drugs and Therapeutics in 
the Center for Innovative Clinical Medicine, Okayama 
University Hospital.
Endourological techniques
The endourological techniques and URS procedures per-
formed at our institution for observation of the upper 
urinary tract and ablation of tumors were previously 
described [11, 12]. All the patients underwent URS using 
“no-touch” technique, which is without any insertion 
of guidewire or ureteral catheter prior to ureteroscope, 
under general anesthesia in a lithotomy position. Before 
the procedures, 10 μM PpIX in a glass vial was observed 
using blue light and the ureteroscopes were confirmed to 
glow red. After cystoscopy, a 6/7.5 Fr semi-rigid uretero-
scope (E-line, Richard Wolf, Knittlingen, Germany) was 
inserted with or without a guidewire as high as possible, 
and then changed to an 8.4 or 7.95 Fr flexible uretero-
scope (URF-P5 or P6, Olympus Co. Ltd., Tokyo, Japan). 
At observation, white light and blue light, switched with 
a foot pedal, were alternately used. When abnormali-
ties, such as a tumor or red fluorescence, were observed, 
cold cup biopsies were performed using 3.3 Fr Forceps™ 
(Cook Medical, Bloomington, IN, USA) without any 
hemostatic technique. Among patients who had preop-
erative positive urine cytology and had no abnormality, 
cold cup biopsies from the renal pelvis and ureter were 
randomly performed. All endourological procedures 
were performed using the VISERA ELITE video system 
and camera head produced by Olympus Co., Ltd.
Data analysis
The observational results and pathological diagnoses, the 
proportion of positive subjects, positive specimens, sen-
sitivity, and specificity were calculated. Adverse events 
were also investigated and severity was categorized using 
the Clavien-Dindo classification.
Results
Characteristics of the 20 patients enrolled in this study 
are shown in Table 1. A total of 5 patients (25%) had posi-
tive preoperative urine cytology and no abnormalities on 
CT urography. Another 5 patients (25%) had abnormali-
ties on CT urography but negative urine cytology.
The median (IQR) time from oral administration of 
5-ALA HCl to biopsy was 246 (227–269) minutes. One 
patient had multiple tumors in the bladder and URS was 
aborted. Among the 19 remaining patients, biopsy was 
not performed because of absence of any abnormality 
in one patient, for whom URS was performed as follow-
up. Fifteen patients were pathologically diagnosed with 
UT-UC and of these, 11 (73.3%) were ALA-PDD posi-
tive. Fourteen of 19 patients were ALA-PDD positive 
and of these, 11 were pathologically diagnosed with UC. 
Among the 50 specimens that are ALA-PDD positive, 25 
(50%) were pathologically diagnosed with UC, 17 (34%) 




Median age (IQR) 71 (67–79)
Gender
 Male 16 (80)
 Female 4 (20)
Co-morbidities
 Malignancy 2 (10)
  Urothelial carcinoma 1 (5)
   UT-UC 0
   Bladder cancer 1 (5)
  Other 0
 Cardiovascular diseases 5 (25)
 Diabetes mellitus 6 (30)
 Other 4 (20)
 None 7 (35)
Laterality
 Right 8 (40)
 Left 9 (45)
 Bilateral 2 (10)
 Unknown 1 (5)
Disease site
 Renal pelvis 6 (30)
  Clinical stage
   < cT2 3 (15)
   ≥ cT2 3 (15)
 Ureter 7 (35)
  Clinical stage
   < cT2 4 (20)
   ≥ cT2 3 (15)
 Unknown (no lesion on CT or MRI) 7 (35)
Urine cytology
 Positive 13 (65)
 Negative 7 (35)
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were not malignant, and the status for 8 (16%) could not 
be determined because the specimens were too small. 
Among the 7 patients that were ALA-PDD positive and 
white light negative (Fig. 1), 4 were diagnosed with CIS. 
Of the 38 specimens from 12 patients that showed no 
abnormalities under examination by both white light and 
ALA-PDD, 11 specimens (28.9%) from 5 patients were 
diagnosed with high grade UC. Comparing white light 
and ALA-PDD, 4 specimens taken from definite tumors 
in 2 patients were ALA-PDD negative but diagnosed 
with UC. On the other hand, 4 specimens which were 
white light negative and ALA-PDD positive taken from 
4 patients were diagnosed with CIS. Of the 31 specimens 
diagnosed with high grade UC, 18 and 13 (58% and 42%) 
were ALA-PDD positive and negative, respectively. For 
specimens from patients with low grade UC, 7 (78%) of 
9 were ALA-PDD positive, but 2 (22%) specimens were 
ALA-PDD negative.
For observational accuracy calculations, 2 patients who 
had pathological diagnoses were excluded and 18 patients 
were enrolled. Based on the results for these 18 patients, 
the sensitivity and specificity of ALA-PDD were calcu-
lated to be 80.0% and 33.3%, respectively, whereas for 
white light observation the respective values were 86.7% 
and 66.7% (Table 2). Considering biopsy specimens that 
could be diagnosed as malignant or benign (n = 92), the 
sensitivity of white light observation and ALA-PDD was 
the same at 62.5%, whereas the specificities were 73.1% 
for white light and 67.3% for ALA-PDD, respectively. 
The PPV and NPV of ALA-PDD were 59.5% and 70.0%, 
respectively. The combined observation had the highest 
sensitivity at 72.5%, but the lowest specificity at 51.9%.
For adverse events, all patients took the first 50  mL 
of drug solution including 5-ALA HCl; however, two 
patients complained of nausea and one vomited 2 h after 
taking 5-ALA HCl. Other symptoms included elevated 
serum aminotransferase that required no additional 
treatment (Clavien-Dindo Grade I) in 6 patients and 
hypotension requiring vasopressors (Grade II) in one 
patient. No allergic episodes, cardiovascular complica-
tions or photosensitivity were observed in our study.
Discussion
In this prospective cohort study to evaluate the effective-
ness of ALA-PDD for UT-UC diagnosis using the VIS-
ERA ELITE video system, the sensitivity and specificity 
were 62.5% and 67.3%, respectively. Of the 38 specimens 
that were randomly biopsied without any abnormality 
under examination by both white light and ALA-PDD, 11 
specimens (28.9%) from 5 patients were diagnosed with 
high grade UC. On the other hand, four biopsy speci-
mens that had abnormal findings with ALA-PDD but not 
with normal white light observation were diagnosed with 
CIS.
Fig. 1 Two different white light negative and ALA-PDD positive lesions using flexible URS (URS-P6, a) and semi-rigid ureteroscopy (Slim line, b) 
followed by diagnosis with carcinoma in situ
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ALA-PDD was approved only for bladder cancer 
by Japanese national health insurance in 2017. This 
approach is expected to have value not only for bladder 
cancer diagnosis but also for treatment, namely com-
plete resection at TURBT [1, 13–16]. On the other hand, 
studies describing photodynamic treatment using ALA 
(ALA-PDT) [17] and some pilot studies [18, 19] involv-
ing ALA-PDD for UT-UC reported that ALA-PDT and 
ALA-PDD could be effective and useful even for UT-UC 
(Table  3). Among studies concerning ALA-PDT and 
-PDD conducted since 2012, most used ureteroscopes 
with a video system produced by Karl Storz SE & Co. 
KG (Tuttlingen, Germany) to diagnose ALA-PDD and 
this technique was shown to have higher accuracy for 
UT-UC diagnosis than methods involving white light [10, 
20–22] and CT urography [22]. Thus, before carrying out 
the present study, we confirmed that PpIX fluorescence 
could be observed using a ureteroscope with the VISERA 
ELITE video system [23]. Our present study revealed 
that sensitivity and specificity values for ALA-PDD for 
UT-UC were lower than other studies for UT-UC and 
slightly lower than those for bladder cancer. These out-
comes could be due to differences in: (1) cystoscopes and 
ureteroscopes; (2) image quality; and (3) video system 
Table 2 Diagnostic accuracy of normal white light observation, ALA-PDD and combined observation
a PLR: positive likelihood ratio
b NLR: negative likelihood ratio
c FPR: false positive ratio
d FNR: false negative ratio
e PPV: positive predictive value
f NPV: negative predictive value
White light ALA-PDD Combined observation
Positive Negative Total Positive Negative Total Positive Negative Total
A. Analysis by participant (n = 18)
Pathological diagnosis
UC 13 2 15 12 3 15 15 0 15
Non-UC 1 2 3 2 1 3 2 1 3
Total 14 4 18 14 4 18 17 1 18
Accuracy of each observa-
tional method
Sensitivity 86.7% Sensitivity 80.0% Sensitivity 100.0%
Specificity 66.7% Specificity 33.3% Specificity 33.3%
PLRa 2.6 PLR 1.2 PLR 1.5
NLRb 0.2 NLR 0.6 NLR -
FPRc 13.3% FPR 20.0% FPR 0.0%
FNRd 33.3% FNR 66.7% FNR 66.7%
PPVe 92.9% PPV 85.7% PPV 88.2%
NPVf 50.0% NPV 25.0% NPV 100.0%
Normal observation ALA-PDD Combined observation
Positive Negative Total Positive Negative Total Positive Negative Total
B. Analysis by biopsy specimen (n = 92)
Pathological diagnosis
Urothelial carcinoma 25 15 40 25 15 40 29 11 40
Non-urothelial carcinoma 14 38 52 17 35 52 25 27 52
Total 39 53 92 42 50 92 54 38 92
Accuracy of each observa-
tional method
Sensitivity 62.5% Sensitivity 62.5% Sensitivity 72.5%
Specificity 73.1% Specificity 67.3% Specificity 51.9%
PLR 2.3 PLR 1.9 PLR 1.5
NLR 0.5 NLR 0.4 NLR 0.5
FPR 37.5% FPR 37.5% FPR 27.5%
FNR 26.9% FNR 32.7% FNR 48.1%
PPV 64.1% PPV 59.5% PPV 53.7%
NPV 71.7% NPV 70.0% NPV 71.1%
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quality. First, images obtained using ureteroscopy are 
dark and small because ureteroscopes are longer and 
thinner than cystoscopes. Second, image processing soft-
ware that optimizes gradations of collected images has 
not been available yet. Third, neither the VISERA ELITE 
nor camera head are designated for ALA-PDD, and thus 
surgeons must insert a special filter between the camera 
head and the endoscope. Use of the newest video system 
such as the VISERA ELITE II could produce a higher 
sensitivity and specificity since we did perform additional 
ex vivo experiments to evaluate which video system was 
better for ALA-PDD using ureteroscopy, and found that 
images produced by the VISERA ELITE II were superior 
to those obtained using VISERA ELITE (Fig. 2).
Interestingly, 11 of the 38 (28.9%) specimens that 
exhibited no abnormalities in either white light or ALA-
PDD examinations were pathologically diagnosed with 
high grade UC. The reasons for this result are unclear, but 
some abovementioned factors may have contributed to 
this outcome. To our knowledge there are no studies that 
examined random biopsy samples taken from the upper 
urinary tract, and additional investigations are needed.
Table 3 Previous studies describing use of ALA-PDT/PDD to diagnose UT-UC
a PDT photodynamic therapy
b PDD photodynamic diagnosis
References Country Study design Objective Sample size Video system supplier Sensitivity (%) Specificity (%)
Waidelich [17] Germany Pilot study PDTa 4 Not stated – –
Somani et al. [18] UK Pilot study PDDb 4 Karl Storz – –
Audenet et al. [19] France Review – – – – –
Ahmad et al. [20] UK Prospective cohort PDD 26 Karl Storz 100 62.5
Aboumarzouk et al. [21] UK Prospective cohort PDD 32 Karl Storz 96 100
Aboumarzouk et al. [22] UK Prospective cohort PDD 30 Karl Storz 94 100
Bondad et al. [25] UK Retrospective Unknown 24 – – –
Kata et al. [9] UK Review PDD – Karl Storz – –
Kata et al. [10] UK Prospective cohort PDD 54 Karl Storz 95.8 96.6
Osman et al. [7] Bahrain Review – – – – –
This study (2019) Japan Prospective cohort PDD 20 VISERA ELITE, Olympus 62.5 67.3%
Fig. 2 Ex vivo experiments for evaluation of ELITE and ELITE II. Cotton swabs containing 0 or 3 μM PpIX are observed using the same flexible URS 
(URS-P6, a) and semi-rigid ureteroscopy (Slim line, b) by white light or blue light (ALA-PDD) at a distance of 5 mm. In both case of flexible URS and 
semi-rigid ureteroscopy, a higher fluorescent intensity with ELITE II (white arrows) compared to ELITE (black arrows) is seen observing the cotton 
swabs containing 3 μM PpIX by blue light
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According to European guidelines [24], diagnostic ure-
teroscopy is strongly recommended to diagnose UT-UC 
tumor type and tumor grade. Furthermore, endoscopic 
management for UT-UC is the primary treatment option 
as a kidney-sparing surgery for patients with low-risk 
tumors (unifocal tumor; tumor size < 2  cm; low-grade 
cytology; low-grade URS biopsy; no invasive aspect on 
CT urography). Although in our study 2 specimens from 
one patient with low grade UC were ALA-PDD negative, 
low grade UC can be positive even in normal white light 
observation. In addition, 4 specimens diagnosed with 
CIS were negative in normal observation but positive in 
ALA-PDD. Hence, our results indicate that ALA-PDD 
might be an effective method for detection of CIS in the 
upper urinary tract.
Adverse events of ALA-PDD have been reported as 
liver toxicity, allergic episode, cardiovascular complica-
tions, photosensitivity, hypotension, nausea and vomit-
ing [9, 25]. In our study, no severe adverse events were 
observed outside of hypotension in one patient because 
of some preventative measures such as oral intake before 
the procedure, shading for 48 h to avoid photosensitivity, 
and other factors. However, one patient who had vom-
ited 2  h after administration of 5-ALA was diagnosed 
with high grade UC while any abnormality could not 
be observed under examination by both white light and 
PDD. The fact suggests the possibility that vomiting had 
some effect on ALA-PDD.
The present study has several limitations. Although this 
pilot study was prospective, it was performed at a single 
center, was non-randomized and included small number 
of patients (n = 20). Second, there were 2 patients who 
underwent protocol URS after endoscopic laser ablation 
and cognitive bias could be associated with the previous 
procedure. Third, we evaluated the usefulness of ALA-
PDD only in the diagnostic process and not the treatment 
process. Fourth, we did not compare endoscopic devices 
including semirigid/flexible ureteroscopes, light cables, 
and video systems, and did not evaluate their compat-
ibility with ALA-PDD. Despite these limitation, the 
ureteroscopy with ALA-PDD might be more useful for 
diagnosis in patients with UT-UC, particularly with CIS.
Conclusions
Our results of this pilot study suggest that ALA-PDD 
using VISERA ELITE is not sufficiently applicable for 
UT-UC. Nevertheless, it might be better particularly 
for CIS than white light and superior results would be 
obtained using VISERA ELITE II video system. Further 
studies on patient selection, endoscopic equipment and 
image processing methods are needed for the broad 
application of ALA-PDD for UT-UC diagnosis.
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